GENE Genetic Technologies: Business Value

Official company branding of gtglabs.com (GENE)

The price action of Genetic Technologies (GENE) reflects a business valuation that currently stands at . Genetic Technologies is expanding its B2B presence by promoting geneType IT solutions for the detection of cancer threats. The development of new multigene panels enables the continuous updating of the diagnostic portfolio. Modern centers in the US and Australia form the operational foundation, where scientific data is applied to preventive healthcare.

GENE (Genetic Technologies) Total Company Value history from 07/04/2022 to 10/28/2026

GENE (Genetic Technologies Limited): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price Genetic Technologies Ltd|GENE - Price Target Chart
- market capitalization data:
Market Capitalization Genetic Technologies|GENE - Enterprise Value
- book capitalization data:
Net Asset Value per Share Genetic Technologies|GENE - Company Book Value|Market Cap to Net Assets Ratio gtglabs.com|GENE - Company Total Assets
- debt and liquidity data:
Debt to Capital Genetic Technologies|GENE - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Genetic Technologies Ltd|GENE - Company Aggregate Debts|Debts to Book Capitalization Genetic Technologies
Summary company analytics:Genetic Technologies (GENE)
Original product of Genetic Technologies

The high-tech capital of Genetic Technologies (GENE), based on genetic expertise and unique R&D, determines the intrinsic value of the business. By analyzing the historical enterprise value trend, an investor can identify the real acquisition price of the asset through the sum of market capitalization and net debt, allowing for an objective assessment of whether the company is overvalued or undervalued relative to its fundamental intellectual resources.

Competitor analysis

Agilent Technologies, Inc. - Total Enterprise Value|Quest (DGX) - Total Company Value|ILMN - Business Value|Enterprise Value EXAS|RVTY (revvity.com) - Total Enterprise Value|Total Company Value BIO|Real Price to Acquire Entire Company Anbio Biotechnology Ltd|Sterigenics - Enterprise Value|Total Enterprise Value QuidelOrtho Inc. (QDEL)|OPK - Enterprise Value|Business Value CareDx Health CDNA|Maravai LifeSciences Holdings, Inc. - Enterprise Value|FLGT: Enterprise Value|Total Company Value Fluidigm|Cytek Corp (CTKB) - Business Value|OSUR (OraSure Technologies) - Enterprise Value|Enterprise Value XGN|Total Company Value MDxHealth (MDXH)|Total Company Value Lucid Diagnostics, Inc. LUCD|PRE: Real Price to Acquire Entire Company|Insight Molecular Diagnostics, Inc. - Total Enterprise Value|Total Company Value TRIB (Trinity Biotech Corp)|PRPH - Company Buyout Price|Ainos - Enterprise Value|CODX (Co-Diagnostics Inc) - Company Buyout Price|HSCS: Total Company Value|Company Buyout Price Biomerica Inc|CDIO: Enterprise Value|Full Takeover Company Value viraxbiolabs.com (VRAX)|BJDX: Enterprise Value|Aspira Women's Health, Inc. - Total Enterprise Value|Accelerate Diagnostics, Inc (AXDX) - Total Company Value|CNTG - Business Value|Enterprise Value ENZ|Total Enterprise Value Fresh2 Group|23andMe (ME) - Real Price to Acquire Entire Company|Aggregate Business Value Psychemedics Corp.